HORIZON-HLTH-2023-ENVHLTH-02-03
HORIZON-HLTH-2023-ENVHLTH-02-03
Programme: Horizon Europe
5 projects · €35,706,915 total EU contribution (project-level) · 60 participating organizations · 20 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€35,706,915
Countries active
Participant organizations by country (headquarters in CORDIS).
- Spain (12)
- Germany (7)
- BE (6)
- Netherlands (5)
- FI (4)
- France (4)
- SE (4)
- UK (3)
- DK (2)
- EL (2)
- Italy (2)
- AT (1)
- CH (1)
- CY (1)
- CZ (1)
- EE (1)
- NO (1)
- PL (1)
- PT (1)
- RS (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- INSERM3 projects · FR
- KI2 projects · SE
- NORWEGIAN INSTITUT FOR WATER RESEARCH2 projects · NO
- STICHTING VU2 projects · NL
- ULIEGE2 projects · BE
- UU2 projects · NL
- CSIC1 projects · ES
- ARISTOTLE UNIVERSITY OF THESSALONIKI1 projects · EL
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 projects · FR
- BFR1 projects · DE
- CMKP1 projects · PL
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN1 projects · DE
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Novel Effect biomarkers for MEtabolic disruptorS: evidence on health Impacts to answer science and policy needS NEMESIS · 101137405 | HORIZON | €7,881,685 | €2,045,513 | Details |
Understanding and preventing the impact of endocrine disruptors on the hypothalamus-pituitary axis in sensitive populations HYPIEND · 101137440 | HORIZON | €6,694,438 | €0 | Details |
Understanding how endocrine disruptors and chemical mixtures of concern target the immune system to trigger or perpetuate disease ENDOMIX · 101136566 | HORIZON | €6,488,875 | €994,466 | Details |
Investigation of endocrine-disrupting chemicals as contributors to progression of metabolic dysfunction-associated steatotic liver disease EDC-MASLD · 101136259 | HORIZON | €7,053,943 | €320,318 | Details |
Merging scientific Evidence with Regulatory practices and Leveraging identification Of endocrine disruptors using New approach methodologies MERLON · 101137411 | HORIZON | €7,587,974 | €319,643 | Details |